Back to Search Start Over

Phosphodiesterase 10A PET radioligand development program: from pig to human.

Authors :
Plisson C
Weinzimmer D
Jakobsen S
Natesan S
Salinas C
Lin SF
Labaree D
Zheng MQ
Nabulsi N
Marques TR
Kapur S
Kawanishi E
Saijo T
Gunn RN
Carson RE
Rabiner EA
Source :
Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2014 Apr; Vol. 55 (4), pp. 595-601. Date of Electronic Publication: 2014 Mar 10.
Publication Year :
2014

Abstract

Unlabelled: Four novel phosphodiesterase 10A (PDE10A) PET tracers have been synthesized, characterized in preclinical studies, and compared with the previously reported (11)C-MP-10.<br />Methods: On the basis of in vitro data, IMA102, IMA104, IMA107, and IMA106 were identified as potential PDE10A radioligand candidates and labeled with either (11)C via N-methylation or with (18)F through an SN2 reaction, in the case of IMA102. These candidates were compared with (11)C-MP-10 in pilot in vivo studies in the pig brain. On the basis of these data, (11)C-IMA106 and (11)C-IMA107 were taken into further evaluation and comparison with (11)C-MP-10 in the primate brain. Finally, the most promising radioligand candidate was progressed into human evaluation.<br />Results: All 5 tracers were produced with good radiochemical yield and specific activity. All candidates readily entered the brain and demonstrated a heterogeneous distribution consistent with the known expression of PDE10A. Baseline PET studies in the pig and baboon showed that (11)C-IMA107 and (11)C-MP-10 displayed the most favorable tissue kinetics and imaging properties. The administration of selective PDE10A inhibitors reduced the binding of (11)C-IMA107 and (11)C-MP-10 in the PDE10A-rich brain regions, in a dose-dependent manner. In the nonhuman primate brain, the tissue kinetics of (11)C-IMA107 and (11)C-MP-10 were well described by a 2-tissue-compartment model, allowing robust estimates of the regional total volume of distribution. Blockade with unlabeled MP-10 confirmed the suitability of the cerebellum as a reference tissue and enabled the estimation of regional binding potential as the outcome measure of specific binding.<br />Conclusion: (11)C-IMA107 was identified as the ligand with the highest binding potential while still possessing reversible kinetics. The first human administration of (11)C-IMA107 has demonstrated the expected regional distribution and suitably fast kinetics, indicating that (11)C-IMA107 will be a useful tool for the investigation of PDE10A status in the living human brain.

Details

Language :
English
ISSN :
1535-5667
Volume :
55
Issue :
4
Database :
MEDLINE
Journal :
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Publication Type :
Academic Journal
Accession number :
24614221
Full Text :
https://doi.org/10.2967/jnumed.113.131409